13 November 2015 - Baxalta Incorporated announced today that the U.S. FDA has approved Adynovate [Antihaemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A.

For more details, go to: http://newsroom.baxalta.com/press-releases/press-release-details/2015/Baxalta-to-Advance-Care-for-Hemophilia-A-Patients-with-FDA-Approval-of-ADYNOVATE-a-Simple-Twice-weekly-Treatment-to-Reduce-Bleeds/default.aspx